Opiates as Antidepressants
The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Abstract
The pathophysiology of mood disorders involves several genetic and social predisposing factors, as well as a dysregulated response to a chronic stressor, i.e. chronic pain. Our present view that depression involves a dysfunction of the monoaminergic system is a result of important clinical and preclinical observations over the past 40 years. In fact, current pharmacological treatment for depression is based on the use of drugs that act mainly by enhancing brain serotonin and noradrenaline neurotransmission by the blockade of the active reuptake mechanism for these neurotransmitters. However, a substantial number of patients do not respond adequately to antidepressant drugs. In view of this, there is an intense search to identify novel targets (receptors) for antidepressant therapy. Opioid peptides and their receptors are potential candidates for the development of novel antidepressant treatment. In this context, endogenous opioid peptides are co-expressed in brain areas known to play a major role in affective disorders and in the action of antidepressant drugs. The actions of endogenous opioids and opiates are mediated by three receptor subtypes (mu, delta and kappa), which are coupled to different intracellular effector systems. Also, antidepressants which increase the availability of noradrenaline and serotonin through the inhibition of the reuptake of both monoamines lead to the enhancement of the opioid pathway. Tricyclic antidepressants show an analgesic effect in neuropathic and inflammatory pain that is blocked by the opioid antagonist naloxone. A compilation of the most significant studies will illustrate the actual and potential value of the opioid system for clinical research and drug development.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rush, A. J., Trivedi, M. H., Wisniewski, S. R., Nierenberg, A. A., Stewart, J. W., Warden, D., Niederehe, G., Thase, M. E., Lavori, P. W., Lebowitz, B. D., et al. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.11.1905 · Cited by 5,643
Nestler, E. J., Barrot, M., DiLeone, R. J., Eisch, A. J., Gold, S. J., & Monteggia, L. M. (2002) · Neuron · doi:10.1016/s0896-6273(02)00653-0 · Cited by 3,217
Millan, M. J. (2002) · Progress in Neurobiology · doi:10.1016/s0301-0082(02)00009-6 · Cited by 3,035
The molecular neurobiology of depression
Krishnan, V., & Nestler, E. J. (2008) · Nature · doi:10.1038/nature07455 · Cited by 2,889 · cited 1×
“At the present time, overwhelming data suggest that depression is not only the cause or the consequence of a disturbance in monoamines [8].”
BackgroundThe mesolimbic dopamine reward circuit in depression
Nestler, E. J., & Carlezon, W. A. (2006) · Biological Psychiatry · doi:10.1016/j.biopsych.2005.09.018 · Cited by 2,059 · cited 2×
“Indeed, some lines of evidence suggest that KOP agonists decrease extracellular concentrations of DA within a key component of the mesolimbic system, the nucleus accumbens [97], which has been implicated in the pathophysiology of depressive conditions [105].”
BackgroundResultIncreased hippocampal bdnf immunoreactivity in subjects treated with antidepressant medication
Chen, B., Dowlatshahi, D., MacQueen, G. M., Wang, J.-F., & Young, L. T. (2001) · Biological Psychiatry · doi:10.1016/s0006-3223(01)01083-6 · Cited by 1,164
Psychotomimesis Mediated by κ Opiate Receptors
Pfeiffer, A., Brantl, V., Herz, A., & Emrich, H. M. (1986) · Science · doi:10.1126/science.3016896 · Cited by 857
The STAR*D project results: A comprehensive review of findings
Warden, D., Rush, A. J., Trivedi, M. H., Fava, M., & Wisniewski, S. R. (2007) · Current Psychiatry Reports · doi:10.1007/s11920-007-0061-3 · Cited by 727
Mice deficient for δ- and μ-opioid receptors exhibit opposing alterations of emotional responses
Filliol, D., Ghozland, S., Chluba, J., Martin, M., Matthes, H. W. D., Simonin, F., Befort, K., Gavériaux-Ruff, C., Dierich, A., LeMeur, M., et al. (2000) · Nature Genetics · doi:10.1038/76061 · Cited by 672 · cited 3×
“In contrast, previous data in KOP knock-out mice demonstrated similar responses to those of wild-type mice in the forced swimming test, disproving the idea that KOP receptors were not involved in depression states [31].”
BackgroundResultThe Dysphoric Component of Stress Is Encoded by Activation of the Dynorphin κ-Opioid System
Land, B. B., Bruchas, M. R., Lemos, J. C., Xu, M., Melief, E. J., & Chavkin, C. (2008) · The Journal of Neuroscience · doi:10.1523/jneurosci.4458-07.2008 · Cited by 601
Pliakas, A. M., Carlson, R. R., Neve, R. L., Konradi, C., Nestler, E. J., & Carlezon, W. A. (2001) · The Journal of Neuroscience · doi:10.1523/jneurosci.21-18-07397.2001 · Cited by 509 · cited 1×
“This selective elevation of CREB function within the nucleus accumbens increases immobility behaviour in the forced swimming test [98] and the KOP antagonist nor-BNI attenuates the behavioural effects of elevated CREB expression within this nucleus [98].”
BackgroundAntidepressant-Like Effects of κ-Opioid Receptor Antagonists in the Forced Swim Test in Rats
Mague, S. D., Pliakas, A. M., Todtenkopf, M. S., Tomasiewicz, H. C., Zhang, Y., Stevens, W. C., Jones, R. M., Portoghese, P. S., & Carlezon, W. A. (2003) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.102.046433 · Cited by 485
Carlezon, W. A., Béguin, C., DiNieri, J. A., Baumann, M. H., Richards, M. R., Todtenkopf, M. S., Rothman, R. B., Ma, Z., Lee, D. Y.-W., & Cohen, B. M. (2006) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.105.092304 · Cited by 390
Buprenorphine Treatment of Refractory Depression
Bodkin, J. A., Zornberg, G. L., Lukas, S. E., & Cole, J. O. (1995) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199502000-00008 · Cited by 346 · cited 1×
“sion [22, 23].”
Newton, S. S., Thome, J., Wallace, T. L., Shirayama, Y., Schlesinger, L., Sakai, N., Chen, J., Neve, R., Nestler, E. J., & Duman, R. S. (2002) · The Journal of Neuroscience · doi:10.1523/jneurosci.22-24-10883.2002 · Cited by 313
Tardito, D., Perez, J., Tiraboschi, E., Musazzi, L., Racagni, G., & Popoli, M. (2006) · Pharmacological Reviews · doi:10.1124/pr.58.1.7 · Cited by 303 · cited 1×
“Neurotrophins, such as brain derived neurotrophic factor (BDNF), play an important role in the therapeutic actions of antidepressants [80].”
BackgroundEffects of κ-opioid receptor ligands on intracranial self-stimulation in rats
Todtenkopf, M. S., Marcus, J. F., Portoghese, P. S., & Carlezon, W. A. (2004) · Psychopharmacology · doi:10.1007/s00213-003-1680-y · Cited by 273
Nonpeptidic δ-opioid Receptor Agonists Reduce Immobility in the Forced Swim Assay in Rats
Broom, D. (2002) · Neuropsychopharmacology · doi:10.1016/s0893-133x(01)00413-4 · Cited by 175 · cited 1×
“More recently, the nonpeptidic delta-opioid agonists (+)-4-[ (R)- -[(2S,5R)-2,5dimethyl-4-(2-propenyl)-1-piperazinyl] - (3 - hydroxyphenyl)methyl]-N,N-diethylbenzamide ((+)BW373U86) and (+)-4[(aR)-a-((2S,5R)-4 - allyl - 2,5 - dimethyl - 1piperazinyl) - 3 - methoxybenzyl]-N,N-diethylbenzamide (SNC80) have been shown to…”
BackgroundChronic antidepressant treatment increases enkephalin levels in n. accumbens and striatum of the rat
de Felipe, M. C., de Ceballos, M. L., Gil, C., & Fuentes, J. (1985) · European Journal of Pharmacology · doi:10.1016/0014-2999(85)90247-x · Cited by 67 · cited 1×
“Furthermore, endogenous opioids have been implicated in the mechanism of action of antidepressant therapies [143, 144].”
Background
Cited by
The Link between Depression and Chronic Pain: Neural Mechanisms in the Brain
Sheng, J., Liu, S., Wang, Y., Cui, R., & Zhang, X. (2017) · Neural Plasticity · doi:10.1155/2017/9724371 · Cited by 775
Opioid receptors: Distinct roles in mood disorders
Lutz, P.-E., & Kieffer, B. L. (2013) · Trends in Neurosciences · doi:10.1016/j.tins.2012.11.002 · Cited by 542
Depression, anxiety and acute pain: links and management challenges
Michaelides, A., & Zis, P. (2019) · Postgraduate Medicine · doi:10.1080/00325481.2019.1663705 · Cited by 428
Fava, M., Memisoglu, A., Thase, M. E., Bodkin, J. A., Trivedi, M. H., de Somer, M., Du, Y., Leigh-Pemberton, R., DiPetrillo, L., Silverman, B., et al. (2016) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2015.15070921 · Cited by 232
“Opioids havebeenused for centuries to treatwhat arenow recognized as mood disorders and were recommended for melancholia in the 19th and early 20th centuries until they were displaced in the 1950s by monoamine-based antidepressants (7, 8).”
BackgroundMonoaminergic system and depression
Perez-Caballero, L., Torres-Sanchez, S., Romero-López-Alberca, C., González-Saiz, F., Mico, J. A., & Berrocoso, E. (2019) · Cell and Tissue Research · doi:10.1007/s00441-018-2978-8 · Cited by 204
Self-citation
Metadata
- Authors
- Berrocoso, E., Sanchez-Blazquez, P., Garzon, J., & Mico, J.
- Venue
- Current Pharmaceutical Design
- Publisher
- Bentham Science Publishers Ltd.
- Published
- 2009-05-01
- Volume
- 15
- Issue
- 14
- Pages
- 1612-1622
- ISSN
- 1381-6128 (ISSN-L)
- OpenAlex
- W2100173292
- Cited by
- 126
- References
- 19
- FWCI
- 4.39
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.